Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Consent of parent or legal guardian required~* Chronic HCV infection~* Screening laboratory values within defined thresholds~Key Exclusion Criteria:~* History of clinically significant illness or any other medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol.~* Co-infection with HIV, acute hepatitis A virus, or hepatitis B virus~* Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage)~* Pregnant or nursing females~* Known hypersensitivity to study medication~* Use of any prohibited concomitant medications as within 28 days of the Day 1 visit~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 12 to < 18 Years Old (Type: EXPERIMENTAL): Participants between 12 to \< 18 years of age weighing ≥ 45 kg will receive LDV/SOF FDC (90/400 mg tablet or 4 x 22.5 mg/100 mg tablets or 8 x 11.25/50 mg granules based on swallowability assessment during screening).~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.~United Kingdom:~* HCV genotypes (GT) 1, 4, 5, or 6 treatment-naive (TN) with or without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1, 4, 5, or 6 treatment-experienced (TE) without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks~* HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks~United States/Australia/New Zealand:~* HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks~* HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks
- 6 to < 12 Years Old (Type: EXPERIMENTAL): Participants between 6 to \< 12 years of age weighing ≥ 17 kg and \< 45 kg will receive LDV/SOF FDC (45/200 mg as 2 x 22.5/100 mg tablets or 4 x 11.25/50 mg granules based on swallowability assessment during screening).~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.~United Kingdom:~* HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks~* HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks~United States/Australia/New Zealand:~* HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks~* HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks
- 3 to < 6 Years Old (Type: EXPERIMENTAL): Participants between 3 to \< 6 years of age weighing ≥ 17 kg will receive LDV/SOF FDC (45/200 mg granules as 4 x 11.25/50 mg packets) and participants weighing \< 17 kg will receive LDV/SOF FDC (33.75/150 mg oral granules as 3 x 11.25/50 mg packets).~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.~United Kingdom:~* HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks~* HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks~United States/Australia/New Zealand:~* HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~* HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks~* HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete